156 related articles for article (PubMed ID: 10854144)
1. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
Koeneman KS; Kao C; Ko SC; Yang L; Wada Y; Kallmes DF; Gillenwater JY; Zhau HE; Chung LW; Gardner TA
World J Urol; 2000 Apr; 18(2):102-10. PubMed ID: 10854144
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
Kubo H; Gardner TA; Wada Y; Koeneman KS; Gotoh A; Yang L; Kao C; Lim SD; Amin MB; Yang H; Black ME; Matsubara S; Nakagawa M; Gillenwater JY; Zhau HE; Chung LW
Hum Gene Ther; 2003 Feb; 14(3):227-41. PubMed ID: 12639303
[TBL] [Abstract][Full Text] [Related]
3. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
4. Co-Targeting Prostate Cancer Epithelium and Bone Stroma by Human Osteonectin-Promoter-Mediated Suicide Gene Therapy Effectively Inhibits Androgen-Independent Prostate Cancer Growth.
Sung SY; Chang JL; Chen KC; Yeh SD; Liu YR; Su YH; Hsueh CY; Chung LW; Hsieh CL
PLoS One; 2016; 11(4):e0153350. PubMed ID: 27054343
[TBL] [Abstract][Full Text] [Related]
5. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
6. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions.
Chung LW; Hsieh CL; Law A; Sung SY; Gardner TA; Egawa M; Matsubara S; Zhau HE
Urology; 2003 Nov; 62(5 Suppl 1):44-54. PubMed ID: 14607217
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Shirakawa T; Terao S; Hinata N; Tanaka K; Takenaka A; Hara I; Sugimura K; Matsuo M; Hamada K; Fuji K; Okegawa T; Higashihara E; Gardner TA; Kao C; Chung LW; Kamidono S; Fujisawa M; Gotoh A
Hum Gene Ther; 2007 Dec; 18(12):1225-32. PubMed ID: 18021019
[TBL] [Abstract][Full Text] [Related]
8. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
[TBL] [Abstract][Full Text] [Related]
9. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
10. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
[TBL] [Abstract][Full Text] [Related]
11. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model.
Cheon J; Ko SC; Gardner TA; Shirakawa T; Gotoh A; Kao C; Chung LW
Cancer Gene Ther; 1997; 4(6):359-65. PubMed ID: 9408606
[TBL] [Abstract][Full Text] [Related]
12. Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Hinata N; Shirakawa T; Terao S; Goda K; Tanaka K; Yamada Y; Hara I; Kamidono S; Fujisawa M; Gotoh A
Int J Urol; 2006 Jun; 13(6):834-7. PubMed ID: 16834676
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
14. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells.
Yeung F; Law WK; Yeh CH; Westendorf JJ; Zhang Y; Wang R; Kao C; Chung LW
J Biol Chem; 2002 Jan; 277(4):2468-76. PubMed ID: 11684680
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity.
Cheon J; Kim HK; Moon DG; Yoon DK; Cho JH; Koh SK
BJU Int; 2000 Apr; 85(6):759-66. PubMed ID: 10759680
[TBL] [Abstract][Full Text] [Related]
16. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
18. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Benjamin R; Helman L; Meyers P; Reaman G
Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
[TBL] [Abstract][Full Text] [Related]
20. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors.
Hsieh CL; Yang L; Miao L; Yeung F; Kao C; Yang H; Zhau HE; Chung LW
Cancer Res; 2002 Jun; 62(11):3084-92. PubMed ID: 12036918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]